Raul Sanchez Lopez2,3,4 , David Baguley1,2,3, Olivia Phillips2,3, Paul Bateman2, Ruth Spriggs2,3 and Ian Wiggins2,3*
1 Nottingham Audiology Services, Nottingham University Hospitals NHS Trust, UK; 2 NIHR Nottingham Biomedical Research Centre, UK; 3 Hearing Sciences, Mental Health & Clinical Neurosciences, School of Medicine, University of Nottingham, UK; 4 Interacoustics Research Unit, Denmark
Large-scale datasets, such as the UK Biobank and the Human Connectome Project, have proved extremely powerful for facilitating research into mechanisms of human health and disease. A limitation of most existing resources, however, is that hearing health phenotypes are captured at a rudimentary level, where even basic pure-tone audiometry data are rarely available. This severely limits the scope of the questions that can be asked of these datasets from an auditory perspective. The Nottingham Hearing BioResource (NHB) represents our effort to begin leveraging the power of large, open, accessible datasets in a way that could transform how we treat and manage hearing loss and hearing-related conditions (e.g., tinnitus, hyperacusis, Ménière’s disease) in future.
At its core, the NHB will provide a comprehensive collection of high-quality, person-centric samples and data focused on hearing health and related domains. Biological samples and data will be made available to academic and commercial researchers around the world in accordance with FAIR (findability, accessibility, interoperability, and reusability) principles. By marrying genetic and biomarker information with measures of noise exposure history, advanced audiological assessment (including extended-high-frequency audiometry, wideband tympanometry, otoacoustic emissions, electrophysiology, auditory perception), and longitudinal tracking of hearing and wider health outcomes, the NHB aims to support research that will radically improve our ability to: 1) understand individual risk; 2) diagnose individual pathology; and 3) predict individual outcomes. At the same time, the NHB will provide a database of well geno/phenotyped individuals who can be recruited in a targeted way into future clinical trials of emerging treatments for hearing loss, such as those based on gene, drug, or cell-based technologies.
With input from a network of international experts, we have been working on several important aspects of the NHB, including: 1) governance, ethical and data access arrangements that align with international norms and published best practice for biobanking; 2) data infrastructure and data standards that will allow for aggregation and interoperability with other datasets around the world; 3) protocols for advanced audiometric assessment, with a particular focus on measures providing information “beyond the audiogram.” In relation to this last aspect, we will report the findings of a small-scale pilot study conducted to establish how the wideband middle ear muscle reflex (MEMR) can be robustly measured using standard clinical equipment.
We look forward to providing an update on progress with the NHB to date, to share learning amongst the hearing community and to prompt discussion.